Abstract:Abstract The development of castration-resistant prostate cancer after androgen deprivation therapy remains the major challenge in the treatment of advanced prostate cancer. Current androgen deprivation therapy targets the action of androgen receptor by reducing circulating androgen level through castration or by disrupting the binding of androgens to the receptor with anti-androgen. Despite the initial efficacy of androgen deprivation therapy, relapse with incurable castration-resistant prostate cancer invariably occurs, constituting the major cause of prostate cancer mortality. Although castration-resistant prostate cancer is no longer responsive to androgen deprivation, the expression and signaling of androgen receptor are maintained. Agents such as abiraterone are effective in prolonging survival in patients with castration-resistant prostate cancer, but even this potent and irreversible CYP17 inhibitor has a relatively short time to disease progression in these patients. One potential mechanism is the prevalent upregulation of the constitutively-active, ligand-binding-domain-truncated androgen receptor splice variants, which have been shown to contribute to castration-resistant tumor growth. Thus, developing effective strategies attacking the androgen receptor itself to reduce its availability is urgently needed in the battle against prostate cancer recurrence during androgen deprivation therapy. Our data show that two potent second-generation selenium-containing drugs, methylseleninic acid (MSA) and methylselenocysteine (MSC), are very effective in decreasing the abundance of both the full-length and the truncated androgen receptor. They not only enhance the efficacy of anti-androgen in both androgen-dependent and castration-resistant prostate cancer cells, but also inhibit prostate tumor relapse after castration in a xenograft model. Our results also show that combination of these agents with anti-androgen produces a robust downregulation of an androgen receptor target, telomerase and its catalytic subunit, telomere reverse transcriptase (hTERT). The combination efficacy is significantly mitigated when hTERT/telomerase expression is restored. In addition, their inhibition of prostate tumor relapse after castration is also accompanied by a pronounced decrease of hTERT. The importance of the findings on hTERT/telomerase lies not only in its key role in regulating cell growth and survival, but also in the association of high hTERT expression with biochemical recurrence in prostate cancer patients undergoing radical prostatectomy and neoadjuvant androgen deprivation therapy. Taken together, our findings provide strong justification and lay the groundwork for an effective therapeutic modality that capitalizes on a new approach of disrupting androgen-receptor-mediated growth response important for the development of castration resistance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4557. doi:10.1158/1538-7445.AM2011-4557

Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer

Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

Abstract 1301: T cell intrinsic androgen receptor activity regulates response to immunotherapy

Abstract 4102: Treatment with androgen receptor targeting vaccines provides an overall survival benefit in AR-V7 expressing tumor models

Functionality of Androgen Receptor-Based Gene Expression Imaging in Hormone Refractory Prostate Cancer

Abstract 4557: A Novel Approach of Disrupting Androgen-Receptor Signaling for Prostate Cancer Intervention

Abstract 683: Vaccination against androgen receptor splice variant induces anti-tumor adaptive immune responses

Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy

Androgen Receptor Antagonists Compromise T Cell Response Against Prostate Cancer Leading to Early Tumor Relapse.

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer

Epitranscriptomic mechanisms of androgen signalling and prostate cancer

Telomerase As an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment.

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Abstract 6282: Novel androgen related gene network in prostate cancer cell model

Integrated Expression Profiling And Chip-Seq Analyses Of The Growth Inhibition Response Program Of The Androgen Receptor

Adeno-Associated Virus-Delivered Short Hairpin-Structured Rna For Androgen Receptor Gene Silencing Induces Tumor Eradication Of Prostate Cancer Xenografts In Nude Mice: A Preclinical Study

Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate